Immunotherapy, Targeted Therapy, and mRNA Vaccines Reshaping Cancer Care

Cancer treatment has undergone a seismic shift in the past decade, moving beyond traditional methods like chemotherapy to more precise, personalized approaches including targeted therapy, immunotherapy, and emerging mRNA-based cancer vaccines.

Targeted therapy attacks specific genetic mutations that fuel cancer growth, unlike chemotherapy which attacks all rapidly dividing cells. These mutations have only been understood in recent years due to advances in genetic research. "We can precisely target those mutations and stop the cancer from growing — as opposed to giving someone chemotherapy, which basically attacks every cell in the body and produces more side effects that cause patients to be sick," explained a McLeod Oncologist. These mutations were not able to be identified and targeted until the last five to 10 years.

Immunotherapy empowers a patient's own immune system to recognize and destroy cancer cells. It has been described as revolutionary in cancers like lung cancer and breast cancer, offering positive responses even when the cancer has spread to other parts of the body, with the potential to achieve remission for a long period of time. Though there can be side effects — since the immune system may also attack healthy cells in rare instances — these are generally manageable.

The biggest breakthrough in cancer treatment in recent years has been advancements in advanced immunotherapeutics and cellular therapeutics, along with antibody drug conjugates. These have transformed how cancers are treated, even in advanced stages, leading to enhanced survival, reduced toxicity, and decreased relapse rates. Immunotherapy is now moving into earlier stages of cancers, including potentially curable food pipe and gastric cancers, to decrease relapse rates and improve survival.

Behind every treatment breakthrough is years of research. The field is evolving rapidly, with three to four new drug approvals for various types of cancer every month. Research not only leads to new therapies but also helps tailor treatments based on a cancer's unique characteristics.

Personalized oncology ensures treatment is specifically tailored to the patient based on their disease biology, pathology, and genomic signatures, providing more precise care than a one-size-fits-all approach.

A groundbreaking development from the University of Florida involves an "off-the-shelf" mRNA-based universal cancer vaccine that may work across multiple cancer types and is already being tested in humans. Published in Nature Biomedical Engineering (Sayour et al., 2025), this approach does not require individualized tumor sequencing at the outset. Instead of training the immune system to recognize a specific cancer protein, the vaccine activates type-I interferons — natural immune messengers that play a central role in innate immunity. By stimulating these early immune pathways, the vaccine helps "reset" immune signals that tumors often hijack to evade detection.

Preclinical studies in mouse models showed the vaccine slowed the growth of melanoma, glioma, and metastatic bone cancer. It also appeared to convert previously resistant tumors into ones that responded better to immune checkpoint inhibitors. Human trials have already begun in patients with aggressive and recurrent cancers, including pediatric glioma and osteosarcoma. The clinical strategy combines an initial off-the-shelf immune-activating dose with a subsequent personalized booster.

Two major areas of research expected to shape cancer care in the next 5 to 10 years are cancer vaccines and liquid biopsies. Multi-cancer early detection tests (MCEDs) — blood tests that can detect multiple types of cancers at very early stages — are set to revolutionize early cancer detection.

To improve cancer awareness and detection, experts recommend integrating cancer screening into public health programs and vaccinating teenage and preteen girls and boys against the human papillomavirus (HPV), which causes cervical, oropharyngeal, and anal cancers. Challenges remain in making these therapies more widely available in terms of both accessibility and affordability.